FDA fi­nal­izes rule on us­ing mas­ter files in bi­o­log­ics ap­pli­ca­tions

The FDA on Fri­day is­sued a fi­nal rule ex­plain­ing how spon­sors can use mas­ter files — sub­mis­sions to the agency with de­tails on their man­u­fac­tur­ing process­es — in bi­o­log­ics ap­pli­ca­tions, with some new tweaks to the draft ver­sion from 2019.

The fi­nal rule makes of­fi­cial what the FDA’s ex­ist­ing ap­proach has been, which is to use mas­ter files con­tain­ing prod­uct-spe­cif­ic in­for­ma­tion in the ap­pli­ca­tions known as BLAs. Un­der the fi­nal­ized rule, pre­vi­ous­ly-ap­proved bi­o­log­ics may con­tin­ue to in­cor­po­rate ref­er­ences to the drug sub­stance, drug sub­stance in­ter­me­di­ate or drug prod­uct en­closed in a mas­ter file, the FDA said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA